Format

Send to

Choose Destination
See comment in PubMed Commons below
Br J Ophthalmol. 2007 Sep;91(9):1244-6. Epub 2007 Apr 12.

Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness.

Author information

1
Wessex Institute for Health R&D, Medical School, University of Southampton, Southampton, UK. raftery@soton.ac.uk

Abstract

Two new drugs provide startling benefits in the treatment of age-related macular degeneration (AMD). The clinical and cost effectiveness of ranibizumab (Lucentis) was compared to that of bevacizumab (Avastin), which costs up to 100 times less. A cost effectiveness model was developed to assess the cost per quality adjusted life year (QALY) over 10 years. For predominantly classic AMD, the efficacy of bevacizumab relative to ranibizumab would have to be around 40% for the latter to achieve 30 k pounds per QALY, a NICE threshold. Similar but worse results applied to the other main forms of AMD, minimally occult and occult with no classic lesions. The price of ranibizumab would have to be drastically reduced for it to be cost effective. Continued unlicensed use of bevacizumab raises ethical, legal and policy questions. Public pressure may be the most potent weapon in persuading Genentech to license bevacizumab for AMD.

PMID:
17431015
PMCID:
PMC1954941
DOI:
10.1136/bjo.2007.116616
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Support Center